Related Experiment Video

Updated: May 7, 2026

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

19.0K

Darizmetinib (HRX215): A Promising 1st-in-Class Liver Regenerating Drug in Phase 1b/2a Clinical Development,

Wolfgang Albrecht1, Roland Selig1,2, Bent Pfaffenrot2

  • 1HepaRegeniX GmbH, Tuebingen 72072, Germany.

Journal of Medicinal Chemistry
|May 6, 2026
PubMed

Insights

Darizmetinib is a novel MKK4 inhibitor discovered for potential liver regeneration therapies. It selectively targets MKK4, modulating the SAPK/MAPK pathway for therapeutic benefit.

Area of Science:

  • Molecular Biology
  • Pharmacology
  • Hepatology

Background:

  • Mitogen-activated protein kinase kinase 4 (MKK4) is crucial in the stress-activated protein kinase (SAPK)/mitogen-activated protein kinase (MAPK) pathway.
  • MKK4 inhibition offers a therapeutic strategy for modulating liver regeneration via pathway rerouting.

Purpose of the Study:

  • To discover and characterize darizmetinib (HRX215), a first-in-class MKK4 inhibitor.
  • To evaluate darizmetinib's preclinical efficacy and safety for potential therapeutic applications.

Main Methods:

  • Structure-activity relationship (SAR) studies were employed to optimize MKK4 inhibition.
  • Preclinical proof-of-concept and in vivo studies assessed efficacy in disease-relevant models.

Main Results:

  • Darizmetinib was successfully engineered for high potency and selectivity against MKK4.
  • Dose-dependent efficacy of darizmetinib was demonstrated in various pharmacological models.

Conclusions:

  • Darizmetinib represents a promising MKK4 inhibitor for therapeutic development.
  • Targeting MKK4 with darizmetinib shows potential for modulating liver regenerative capacity.

More Related Videos

An Efficient Protocol to Assess ERK Activity Modulation in Early Zebrafish Noonan Syndrome Models via Live FRET Microscopy and Immunofluorescence09:58

An Efficient Protocol to Assess ERK Activity Modulation in Early Zebrafish Noonan Syndrome Models via Live FRET Microscopy and Immunofluorescence

Published on: May 2, 2025

877
Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

8.5K

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.2K
Liver Regeneration01:24

Liver Regeneration

The liver is an important organ in vertebrates that plays an essential role in metabolism. It is also responsible for storing and redistributing nutrients such as carbohydrates, fats, and vitamins in the body. Additionally, the liver releases bile salts which are critical for digesting food and eliminating toxic metabolites from the body.
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are...
4.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K